Eli Lilly and Company (NYSE:LLY) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by Stanley Muller on Aug 6th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) has received a consensus rating of “Moderate Buy” from the thirty-one ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-four have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $1,289.3571.

A number of equities research analysts have recently weighed in on LLY shares. The Goldman Sachs Group restated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Wolfe Research restated an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a report on Monday, June 22nd. Finally, Citigroup boosted their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th.

Get Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,170.30 on Thursday. The company’s fifty day moving average price is $1,156.45 and its 200-day moving average price is $1,045.49. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 41.57, a PEG ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $2.22. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.69 billion. During the same quarter in the prior year, the firm earned $6.31 earnings per share. The firm’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 34.71 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Strong Q2 beat and raised outlook: Lilly reported $22.97 billion in second-quarter revenue, up approximately 48% year over year and well above the roughly $20.7 billion consensus estimate. Non-GAAP EPS of $8.38 also exceeded expectations of about $6.16. Management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and provided EPS guidance of $35.50-$36.50. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Positive Sentiment: GLP-1 demand remains the main catalyst: Sales of Mounjaro and Zepbound surged, together accounting for nearly two-thirds of quarterly revenue; Mounjaro sales reportedly rose 91%. Strong volume and international expansion are driving growth and helping Lilly widen its lead over Novo Nordisk in the obesity-drug market. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
Positive Sentiment: Wall Street remains bullish: Analysts continue to see upside after the beat-and-raise quarter, with at least one major analyst increasing its price target. Coverage describes the results as strengthening Lilly’s long-term investment thesis. We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Positive Sentiment: Pipeline and competitive momentum: Lilly is expanding early access to experimental obesity treatment retatrutide, while investigational cancer drug olomorasib received an FDA breakthrough therapy designation. Novo Nordisk’s recent key miss further highlights Lilly’s competitive advantage in GLP-1 therapies.
Neutral Sentiment: Key risks remain: Lilly’s growth is heavily concentrated in GLP-1 medicines, and manufacturing capacity could limit its ability to meet demand. At roughly $1.10 trillion in market value and a forward-looking premium valuation, the stock may remain sensitive to future execution, supply, and clinical results.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently made changes to their positions in LLY. Brighton Jones LLC increased its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Schnieders Capital Management LLC. raised its holdings in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC bought a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth $749,000. 82.53% of the stock is owned by institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.